Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-04895162 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PF-04895162 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-04895162 | DRUG | Tablets, 300 mg, single, 1 day |
| Placebo | DRUG | Tablets, twice a day, 14 days |
Inclusion Criteria: 1. Healthy male and/or female subjects of non-child bearing potential between the ages of 18 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and puls...
PF-04895162 is an investigational small molecule being studied in healthy volunteers. It is not approved for any disease and is in clinical development to evaluate its safety, toleration, and plasma concentration profile. The drug is being developed by Pfizer, Inc. (PFE).
The molecular target of PF-04895162 has not been disclosed. It is a small molecule in Phase 1 clinical development, but its specific mechanism of action is not publicly available from the trial information provided.
PF-04895162 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetics in healthy participants.
PF-04895162 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains under evaluation for its safety and toleration profile.
PF-04895162 has one completed Phase 1 trial, NCT01691274, which evaluated the safety, toleration, and plasma concentration of multiple oral doses in healthy adults. The trial enrolled 10 participants in the United States and was randomized, double-blind, and placebo-controlled.